174 related articles for article (PubMed ID: 17367119)
21. Drug resistance of HIV-1 protease against JE-2147: I47V mutation investigated by molecular dynamics simulation.
Bandyopadhyay P; Meher BR
Chem Biol Drug Des; 2006 Feb; 67(2):155-61. PubMed ID: 16492163
[TBL] [Abstract][Full Text] [Related]
22. Drug-resistant molecular mechanism of CRF01_AE HIV-1 protease due to V82F mutation.
Liu X; Xiu Z; Hao C
J Comput Aided Mol Des; 2009 May; 23(5):261-72. PubMed ID: 19219633
[TBL] [Abstract][Full Text] [Related]
23. Structure, dynamics and solvation of HIV-1 protease/saquinavir complex in aqueous solution and their contributions to drug resistance: molecular dynamic simulations.
Wittayanarakul K; Aruksakunwong O; Sompornpisut P; Sanghiran-Lee V; Parasuk V; Pinitglang S; Hannongbua S
J Chem Inf Model; 2005; 45(2):300-8. PubMed ID: 15807491
[TBL] [Abstract][Full Text] [Related]
24. Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen.
Doualla-Bell F; Avalos A; Gaolathe T; Mine M; Gaseitsiwe S; Ndwapi N; Novitsky VA; Brenner B; Oliveira M; Moisi D; Moffat H; Thior I; Essex M; Wainberg MA
Antimicrob Agents Chemother; 2006 Jun; 50(6):2210-3. PubMed ID: 16723586
[TBL] [Abstract][Full Text] [Related]
25. Structural and energetic analysis on the complexes of clinically isolated subtype C HIV-1 proteases and approved inhibitors by molecular dynamics simulation.
Matsuyama S; Aydan A; Ode H; Hata M; Sugiura W; Hoshino T
J Phys Chem B; 2010 Jan; 114(1):521-30. PubMed ID: 20055526
[TBL] [Abstract][Full Text] [Related]
26. Low accumulation of L90M in protease from subtype F HIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism.
Calazans A; Brindeiro R; Brindeiro P; Verli H; Arruda MB; Gonzalez LM; Guimaraes JA; Diaz RS; Antunes OA; Tanuri A
J Infect Dis; 2005 Jun; 191(11):1961-70. PubMed ID: 15871131
[TBL] [Abstract][Full Text] [Related]
27. Molecular Dynamics Simulations of HIV-1 Protease Suggest Different Mechanisms Contributing to Drug Resistance.
Wartha F; Horn AH; Meiselbach H; Sticht H
J Chem Theory Comput; 2005 Mar; 1(2):315-24. PubMed ID: 26641303
[TBL] [Abstract][Full Text] [Related]
28. Comparative studies on inhibitors of HIV protease: a target for drug design.
Jayaraman S; Shah K
In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
[TBL] [Abstract][Full Text] [Related]
29. The impact of active site mutations of South African HIV PR on drug resistance: Insight from molecular dynamics simulations, binding free energy and per-residue footprints.
Ahmed SM; Maguire GE; Kruger HG; Govender T
Chem Biol Drug Des; 2014 Apr; 83(4):472-81. PubMed ID: 24267738
[TBL] [Abstract][Full Text] [Related]
30. Exploring the drug resistance mechanism of active site, non-active site mutations and their cooperative effects in CRF01_AE HIV-1 protease: molecular dynamics simulations and free energy calculations.
C S V; Tamizhselvi R; Munusami P
J Biomol Struct Dyn; 2019 Jul; 37(10):2608-2626. PubMed ID: 30051758
[TBL] [Abstract][Full Text] [Related]
31. The contribution of naturally occurring polymorphisms in altering the biochemical and structural characteristics of HIV-1 subtype C protease.
Coman RM; Robbins AH; Fernandez MA; Gilliland CT; Sochet AA; Goodenow MM; McKenna R; Dunn BM
Biochemistry; 2008 Jan; 47(2):731-43. PubMed ID: 18092815
[TBL] [Abstract][Full Text] [Related]
32. Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezácová P; Brynda J; Pokorná J; Plesek J; Grüner B; Grantz Sasková K; Václavíková J; Král V; Konvalinka J
J Med Chem; 2008 Aug; 51(15):4839-43. PubMed ID: 18598016
[TBL] [Abstract][Full Text] [Related]
33. Molecular dynamics and free energy studies on the wild-type and mutated HIV-1 protease complexed with four approved drugs: mechanism of binding and drug resistance.
Alcaro S; Artese A; Ceccherini-Silberstein F; Ortuso F; Perno CF; Sing T; Svicher V
J Chem Inf Model; 2009 Jul; 49(7):1751-61. PubMed ID: 19537723
[TBL] [Abstract][Full Text] [Related]
34. Genotypic resistance profiles in antiretroviral-naive HIV-1 infections before and after initiation of first-line HAART: impact of polymorphism on resistance to therapy.
Sukasem C; Churdboonchart V; Sukeepaisarncharoen W; Piroj W; Inwisai T; Tiensuwan M; Chantratita W
Int J Antimicrob Agents; 2008 Mar; 31(3):277-81. PubMed ID: 18182278
[TBL] [Abstract][Full Text] [Related]
35. Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance.
Hou T; Yu R
J Med Chem; 2007 Mar; 50(6):1177-88. PubMed ID: 17300185
[TBL] [Abstract][Full Text] [Related]
36. A molecular dynamics study comparing a wild-type with a multiple drug resistant HIV protease: differences in flap and aspartate 25 cavity dimensions.
Seibold SA; Cukier RI
Proteins; 2007 Nov; 69(3):551-65. PubMed ID: 17623840
[TBL] [Abstract][Full Text] [Related]
37. Identification of human immunodeficiency virus type 1 non-B subtypes and antiretroviral drug-resistant strains in United States blood donors.
Brennan CA; Stramer SL; Holzmayer V; Yamaguchi J; Foster GA; Notari Iv EP; Schochetman G; Devare SG
Transfusion; 2009 Jan; 49(1):125-33. PubMed ID: 18954404
[TBL] [Abstract][Full Text] [Related]
38. A phenylnorstatine inhibitor binding to HIV-1 protease: geometry, protonation, and subsite-pocket interactions analyzed at atomic resolution.
Brynda J; Rezacova P; Fabry M; Horejsi M; Stouracova R; Sedlacek J; Soucek M; Hradilek M; Lepsik M; Konvalinka J
J Med Chem; 2004 Apr; 47(8):2030-6. PubMed ID: 15056001
[TBL] [Abstract][Full Text] [Related]
39. Non-infectious fluorimetric assay for phenotyping of drug-resistant HIV proteinase mutants.
Majerová-Uhlíková T; Dantuma NP; Lindsten K; Masucci MG; Konvalinka J
J Clin Virol; 2006 May; 36(1):50-9. PubMed ID: 16527535
[TBL] [Abstract][Full Text] [Related]
40. New insights into the in silico prediction of HIV protease resistance to nelfinavir.
Antunes DA; Rigo MM; Sinigaglia M; de Medeiros RM; Junqueira DM; Almeida SE; Vieira GF
PLoS One; 2014; 9(1):e87520. PubMed ID: 24498124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
